Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
(36 sites) United States
UC San Diego Moores Cancer Center, La Jolla, California Sarah Cannon Research Institute at HealthONE, Denver, Colorado Yale Cancer Center, New Haven, Connecticut Florida Cancer Specialist-Lake Mary, Lake Mary, Florida University of Illinois, Chicago, Illinois Dana Farber Cancer Institute, Boston, Massachusetts START - Midwest - EDOS, Grand Rapids, Michigan Montefiore Einstein Cancer Center, The Bronx, New York Mary Crowley Medical Research Center, Dallas, Pennsylvania Abramson Cancer Center;Univ of Pennsylvania, Philadelphia, Pennsylvania SCRI Oncology Partners, Nashville, Tennessee Australia
St Vincent's Hospital Sydney, Darlinghurst, New South Wales Peter Maccallum Cancer Centre, Parkville, Victoria Canada
British Columbia Cancer Agency, Vancouver, British Columbia Princess Margaret Cancer Centre, Toronto, Ontario Sir Mortimer B Davis Jewish General Hospital, Montreal, Quebec Israel
Rambam Health Care Campus, Haifa Hadassah University Hospital - Ein Kerem, Jerusalem The Chaim Sheba Medical Center, Ramat Gan Tel Aviv Sourasky Medical Center PPDS, Tel Aviv Singapore
National University Hospital, Singapore National Cancer Centre, Singapore South Korea
Seoul National University Bundang Hospital, Seongnam Asan Medical Center., Seoul Seoul National University Hospital, Seoul Severance Hospital, Yonsei University Health System, Seoul Spain
Instituto de Investigacion Oncologica Vall dHebron (VHIO) - EPON, Barcelona Hospital Universitario 12 de Octubre, Madrid START Madrid_Hospital Universitario HM Sanchinarro_CIOCC, Madrid Hospital Universitario Virgen de la Victoria, Málaga Hospital Universitario Virgen del Rocio - PPDS, Seville Hospital Clinico Universitario de Valencia, Valencia United Kingdom
Western General Hospital;Edinburgh Cancer Center, Edinburgh, Midlothian NIHR UCLH Clinical Research Facility, London Royal Marsden Hospital - Surrey, Sutton